Citations

Showing 10 of 108083 citations.

TDP‐43 pathology effect on volume and flortaucipir uptake in Alzheimer's disease
Carlos, Arenn F. , Tosakulwong, Nirubol , Weigand, Stephen D. , Petersen, Ronald C. , Nguyen, Aivi T. , Reichard, R. Ross , Lowe, Val J. , Whitwell, Jennifer L. , Josephs, Keith A. , Nguyen, Aivi T , Carlos, Arenn F , Senjem, Matthew L. , Schwarz, Christopher G. , Knopman, David S. , Boeve, Bradley F. , Dickson, Dennis W. , Jack, Clifford R.

Mayo Clinic

Alzheimer's & Dementia | December 4, 2022 | Volume: 19 | Issue: 6 | Pages: 2343-2354

10.1002/alz.12878 | PMID 36463537 Get It

AbstractIntroductionAlzheimer's disease (AD) patients ≥70 years show smaller medial temporal volumes despite less 18F‐flortaucipir‐positron emission tomography (PET) uptake than younger counterparts. We investigated whether TAR DNA‐binding protein 43 (TDP‐43) was contributing to this volume‐uptake mismatch.MethodsSeventy‐seven participants with flortaucipir‐PET and volumetric magnetic resonance imaging underwent postmortem AD and TDP‐43 pathology assessments. Bivariate‐response linear regression estimated the effect of age and TDP‐43 pathology on volume and/or flortaucipir standardized uptake volume ratios of the hippocampus, amygdala, entorhinal, inferior temporal, and midfrontal cortices.ResultsOlder participants had lower hippocampal volumes and overall flortaucipir uptake. TDP‐43‐immunoreactivity correlated with reduced medial temporal volumes but was unrelated to flortaucipir uptake. TDP‐43 effect size was consistent across the age spectrum. However, at older ages, the cohort mean volumes moved toward those of TDP‐43‐positives, reflecting the increasing TDP‐43 pathology frequency with age.DiscussionTDP‐43 pathology is a relevant contributor driving the volume‐uptake mismatch in older AD participants.Highlights TDP‐43 pathology affects medial temporal volume loss but not tau radiotracer uptake. Greater TDP‐43 pathology effect is seen in old age due to its increasing frequency. TDP‐43 pathology is a relevant driver of the volume‐uptake mismatch in old AD patients.
Dexamethasone versus prednisone/prednisolone in the management of pediatric patients with acute asthmatic exacerbations: a systematic review and meta-analysis
Dahan, Elise, Ghazal, Nour El , Nakanishi, Hayato , Haddad, Joe El , Tosovic, Danijel , Than, Christian A., Stiasny, David, Than, Christian A. , Matar, Reem H, Than, Christian A , El Ghazal, Nour , Matar, Reem , Beran, Azizullah

Mayo Clinic

Journal of Asthma | December 3, 2022 | Volume: 60 | Issue: 8 | Pages: 1481-1492

10.1080/02770903.2022.2155189 | PMID 36461938 Get It

Retinal Vasculopathy With Cerebral Leukoencephalopathy and Systemic Manifestations: Critical Role of Retina Specialists
Houghton, Odette M. , Dhamija, Radhika , Dhamija, Radhika , Carter, Jonathan

Mayo Clinic

Journal of VitreoRetinal Diseases | December 3, 2022 | Volume: 7 | Issue: 2 | Pages: 171-177

10.1177/24741264221129095 | PMID 37006667 Get It

Purpose: To describe a case of retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S) to enhance early recognition of this often-missed diagnosis. Methods: A case report is presented. Results: A 50-year-old woman with a history of Raynaud phenomenon, memory difficulties, and a family history of strokes was referred for evaluation of a bilateral, small-vessel, occlusive disease refractory to immunosuppressive therapy. An extensive workup for treatable causes was unrevealing. Fifteen months after presentation, brain imaging showed white-matter lesions and dystrophic calcification, which led to the discovery of a pathogenic variant in TREX1 and the diagnosis of RVCL-S. Conclusions: Retina specialists play a critical role in the timely diagnosis of RVCL-S. Although the findings in this condition can mimic those in other common retinal vascular disorders, there are key characteristics that increase the suspicion for RVCL-S. Early recognition might decrease unnecessary therapies and procedures.
Blood volume and chronic kidney disease in heart failure – Can volume expansion help balance the Cardio‐Renal Axis for better clinical outcomes?
Miller, Wayne L. , Fudim, Marat , Mullan, Brian P., Miller, Wayne L.

Mayo Clinic

Physiological Reports | December 3, 2022 | Volume: 10 | Issue: 23 | Pages: No page available

10.14814/phy2.15526 | PMID 36461656 Get It

AbstractIntravascular volume is largely regulated by the kidneys but how differences in intravascular volume profiles interact with chronic kidney disease (CKD) to influence outcomes in chronic heart failure (HF) has not been explored. Our hypothesis was that a greater degree of volume expansion (VE) would moderate the impact of CKD on HF‐related clinical outcomes. Quantitative blood volume (BV) data were available in 137 patients at the time of hospital discharge using a nuclear medicine radiolabeled albumin indicator‐dilution technique. The study patients were stratified by the cohort median glomerular filtration rate (GFR, 44 ml/min/1.73 m2). An a priori cut‐point of ≥+25% above normal BV was then used to further stratify the two GFR subgroups and prospectively analyzed for 1‐year HF‐related mortality or 1st re‐hospitalization. Persistent BV expansions ≥+25% were present in 51% of the cohort. In the subgroup with GFR above the median (N = 68) greater or lesser BV expansion from +25% did not differentiate outcomes. However, in the subgroup with GFR below the median (N = 69), BV expansion‐stratified risk (log‐rank p = 0.022) with <+25% VE associated with poorer outcomes, while VE ≥ + 25% was associated with lower risk and comparable to GFR above the median. In patients with chronic HF, significant intravascular VE and CKD are common co‐existing conditions. The presence of larger VE, however, appears to be a factor mitigating the impact of declining renal function on clinical outcomes, and as an element of volume pathophysiology warrants further study.
Predictors and Interrelationship of Patient‐Reported Outcomes in Antiphospholipid Syndrome: A Cross‐Sectional Study
Weiner, Julia, Smith, Tristin , Hoy, Claire K., Sarosh, Cyrus , Madison, Jacqueline A. , Ambati, Amala, Tambralli, Ajay , Peters, Noah F., Packel, Corinne, Gockman, Kelsey, Zuo, Yu , Briceño, Emily M. , Knight, Jason S , Zuo, Yu , Sarosh, Cyrus , Madison, Jacqueline A , Ambati, Amala, Nagaraja, Vivek

Mayo Clinic

ACR Open Rheumatology | December 3, 2022 | Volume: 5 | Issue: 1 | Pages: 28-37

10.1002/acr2.11512 | PMID 36461647 Get It

ObjectiveThis study assessed patient‐reported outcomes (PROs) in individuals with persistently positive antiphospholipid antibodies (aPL) to better understand how living with aPL may affect their quality of life.MethodsPatients completed Patient‐Reported Outcomes Measurement Information System Physical Function (PF) and Cognitive Function (CF) Short Forms as well as the pain intensity (PI) rating (scale of 1‐10). Patients were characterized for demographics, clinical manifestations of antiphospholipid syndrome (APS), cardiovascular risk factors, laboratory test results, and medication usage. Multivariate modeling was done via linear regression.ResultsOf 139 patients, 89 had primary APS, 21 had secondary APS, and 29 had persistent aPL without meeting clinical criteria for APS. The average T scores (±SD) for PF and CF were 45.4 ± 9.2 and 48.6 ± 11.6, respectively; the average for PI was 3.0 ± 2.6. Approximately half of the patients (47%) endorsed at least mild impairment in PF (T score < 45). Mean PF, CF, and PI did not differ between diagnostic groups. Individuals who endorsed more impairment on one measure also tended to endorse more impairment on another (Pearson r = 0.43‐0.59). In the multivariate models, age, smoking, pain medications, and serotonergic medications were associated with impairment in at least one PRO domain. The Damage Index for APS was significantly correlated with both PF and CF.ConclusionIndividuals living with APS endorsed more impairment in PF (and potentially CF) than expected for the general population. The relationship between certain medications and PROs warrants further study, as does the longitudinal trajectory of these and other PROs.
Cardiac amyloidosis—An underdiagnosed cause of heart failure: A case report and review of literature
Parmar, Kanak , Sethi, Pooja , Tijani, Lukman, Hurst, Philip , Pertuz, Gaspar Del‐Rio, Argueta‐Sosa, Erwin , Benjanuwattra, Juthipong , Hurst, Philip, Pertuz, Gaspar Del Rio

Mayo Clinic

Clinical Case Reports | December 3, 2022 | Volume: 10 | Issue: 12 | Pages: No page available

10.1002/ccr3.6525 | PMID 36478969 Get It

Abstract Restrictive cardiomyopathy secondary to cardiac amyloidosis is an underdiagnosed, but treatable, cause of heart failure involving an extracellular deposition of misfolded protein. Hereby, we report a case of a female patient with history of nephrotic syndrome for 1 year who subsequently presented with symptoms of heart failure. The findings on cardiac imaging supported the suspicion of cardiac amyloidosis. Further laboratory workup for amyloidosis was pursued along with endomyocardial biopsy which confirmed amyloidosis‐AL type. Patient was started on chemotherapy. The case underscores the importance of a timely diagnosis with the help of symptomatology and imaging along with a multidisciplinary approach for patient care.
GPe Astrocytes and Prototypic Neurons Selectively Represent Routine Formation
Yang, Minsu Abel , Hong, Sa‐Ik , Kang, Shinwoo , Lee, Jeyeon , Choi, Doo‐Sup , Choi, Doo-Sup , Song, Minryung , Lee, Sang Wan

Mayo Clinic

No container title available | December 2, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2286086/v1 Get It

Abstract The external globus pallidus (GPe) guides action selection. However, it remains elusive how diverse GPe cells engage in routine formation while learning action sequences in repetitive reward-seeking conditioning. Here, we investigated the Ca2+ signals of GPe cells during routine formation. We found that the dynamics of astrocytes and prototypic neurons’ activities are associated with the refinement of the action sequence, which enables cost-effective reward-seeking.
RNA-sequencing comparison of pneumonectomy and bleomycin reveals anti-fibrotic mechanisms of lung fibroblasts
Dresler, Sara R. , Meridew, Jeffrey A., Choi, Kyoung Moo , Haak, Andrew J. , Tschumperlin, Daniel J. , Wellmerling, Jack , Tan, Qi

Mayo Clinic

No container title available | December 2, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2306746/v1 Get It

Abstract Background Idiopathic pulmonary fibrosis (IPF) is characterized by pathological accumulation of scar tissue in the lung parenchyma. Many of the processes that are implicated in fibrosis, such as matrix deposition also occur following pneumonectomy (PNX). However, fibrosis does not occur. Since fibroblasts are the major cell type responsible for extracellular matrix production, we hypothesized that comparing their responses to PNX and bleomycin (BLM) would unveil key differences in the role they play during regulated and fibrotic lung growth. Methods RNA-sequencing was performed on flow cytometry-sorted fibroblasts from mouse lungs 14 days after bleomycin challenge, PNX, or sham. Pathway and transcription factor binding motif enrichment analysis were performed to characterize RNA-sequencing data. Normal human lung fibroblasts (NHLFs) were used as a cell culture model to validate targets. Results RNA-sequencing analysis revealed similar biological processes to be involved in both responses, including signaling by transforming growth factor-β (TGF-β1) and tumor necrosis factor-α. Transcription factor binding motif enrichment predicted erythroid transformation specific (ETS) superfamily members to play a key role in the response to BLM, whereas nuclear factor-κB (NF-κB) and activator protein-1 (AP-1) were predicted to orchestrate much of the response to PNX. Itpkc, encoding inositol triphosphate kinase C, was a gene uniquely up-regulated by PNX and a likely AP-1 target. ITPKC overexpression in NHLFs antagonized the fibrotic effect of TGF-β1. RNA-sequencing analysis of primary NHLFs overexpressing ITPKC further supported its role in repressing collagen production and predicted it as an activator of canonical NF-κB signaling. ITPKC overexpression showed considerable overlap with the innate immune signaling seen following PNX. Conclusion Taken together, our RNA-sequencing analysis suggests that during post-PNX lung growth, AP-1 activates ITPKC to promote canonical NF-κB signaling to prevent fibrogenesis. Future studies to understand this lack of ITPKC induction during fibrotic injury may identify attractive therapeutic targets.
Development of SOS1 Inhibitor-Based Degraders to Target KRAS-Mutant Colorectal Cancer
Bian, Yujia , Alem, Diego , Beato, Francisca , Hogenson, Tara L. , Cai, Jianfeng , Fernández-Zapico, Martín E. , Tan, Aik Choon , Fleming, Jason B. , Yuan, Yu, Cai, Jianfeng , Fernandez-Zapico, Martin, Xie, Hao , Tan, Aik Choon , Yang, Xinrui , Jiang, Kun , Wee, Wen , Lawrence, Nicholas J. , Xie, Hao

Mayo Clinic

Journal of Medicinal Chemistry | December 2, 2022 | Volume: 65 | Issue: 24 | Pages: 16432-16450

10.1021/acs.jmedchem.2c01300 | PMID 36459180 Get It